Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Mesothelioma × Ramucirumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Stomach Neoplasms 36 Carcinoma, Non-Small-Cell Lung 30 Neoplasms 10 Neoplasm Metastasis 9 Lung Neoplasms 9 Adenocarcinoma 9 Colorectal Neoplasms 8 Esophageal Neoplasms 7 Carcinoma, Hepatocellular 7 Colonic Neoplasms 5 Carcinoma, Renal Cell 5 Breast Neoplasms 5 Adenocarcinoma Of Esophagus 4 Urinary Bladder Neoplasms 3 Urethral Neoplasms 3 Rectal Neoplasms 3 Melanoma 3 Liver Neoplasms 3 Carcinoma, Transitional Cell 3 Biliary Tract Neoplasms 3 Ureteral Neoplasms 2 Thymoma 2 Squamous Cell Carcinoma of Head and Neck 2 Solid Tumors 2 Sarcoma 2 Recurrence 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Non-small Cell Lung Cancer Metastatic 2 Malignant Solid Tumor 2

Interventions

Pemetrexed 35 Cisplatin 30 pembrolizumab 19 Nivolumab 15 Carboplatin 15 Ipilimumab 11 Gemcitabine 9 Cyclophosphamide 7 durvalumab 6 fludarabine 5 Bevacizumab 5 Radiotherapy, Intensity-Modulated 4 Dexamethasone 4 tremelimumab 3 tazemetostat 3 olaparib 3 niraparib 3 anetumab ravtansine 3 Vinorelbine 3 Paclitaxel 3 LMB-100 3 Imatinib Mesylate 3 Fluorouracil 3 Cerebral Decortication 3 Blood Specimen Collection 3 sargramostim 2 fludarabine phosphate 2 defactinib 2 budigalimab 2 belinostat 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03560973 2025-03-13

RAMES

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 2 Completed

Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡